A screen of the publicly available TCGA-PRAD (mostly untreated primary PCa and adjacent benign samples) (Fig. 2G) and SU2C-PRAD [(heavily treated primary castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC) samples)] (Fig. 2H) datasets revealed that MAO-A mRNA expression is significantly positively correlated with GR activity. This evidence concerns the gene NR3C1 and posterior cortical atrophy.